Source: Biospectrum Asia

Ethypharm: French firm Ethypharm expands Mesalazine portfolio in China for IBD treatment

French firm Ethypharm expands its footprint in China

Read full article »
Ethypharm's Competitors | Ethypharm's News | Ethypharm's Financials
Stay up-to-date with the latest news on Ethypharm
Est. Annual Revenue
$100-500M
Est. Employees
1.0-5.0K
Bertrand Deluard's photo - CEO of Ethypharm

CEO

Bertrand Deluard

CEO Approval Rating

81/100

Read more
Stay up-to-date with the latest news on Ethypharm